Sellas Life Sciences Group Inc. recently held a corporate presentation discussing its advancements in the field of novel therapies, specifically focusing on two clinical-stage assets with potential first and best-in-class status. The company's lead indication is acute myeloid leukemia $(AML.AU)$ for both therapies. The presentation highlighted Galinpepimut-S $(GPS.AU)$, an innovative immunotherapy targeting the Wilms Tumor 1 (WT1) antigen, currently in a Phase 3 REGAL clinical trial for AML patients achieving a second complete remission (CR2). Interim analysis demonstrated potential efficacy, with a final analysis expected in 2025. GPS has shown promising results in previous trials, with a median overall survival $(OS)$ notably higher than expected for relapsed/refractory AML patients. Additionally, the company discussed SLS009 (tambiciclib), a novel CDK9 inhibitor, which met all primary endpoints in a Phase 2 trial for relapsed/refractory AML. The presentation also covered regulatory designations received from the FDA and EMA. You can access the full presentation through the link below.